Tremfya and Icotyde Take Center Stage in J&J's Post-Stelara Immunology Strategy

What happened

Johnson & Johnson is positioning Tremfya and the newly approved Icotyde as the key growth drivers for its immunology franchise as Stelara faces accelerating biosimilar erosion. The DeepValue master report highlights that Tremfya's expansion into inflammatory bowel disease and Icotyde's novel mechanism are critical to offsetting the $4.8 billion quarterly revenue decline from Stelara. While the base case assumes ex-Stelara growth of 9-11%, the risk of lower adoption or competitive pressure (e.g., from Skyrizi) remains. J&J's 2026 guidance of ~$100.5 billion revenue and $11.53 adjusted EPS already prices in a successful transition, but execution risks and unresolved talc litigation cap upside. The stock, after a 46.6% rally in 12 months, trades at 20.8x trailing earnings, offering a limited margin of safety without a pullback or clearer legal outcomes.

Implication

Near term, the focus shifts to quarterly sales data for Tremfya and Icotyde to validate whether they can sustain double-digit growth. If both deliver strong momentum in 2026, the thesis of a successful Stelara replacement strengthens, but any deceleration could trigger a de-rating. Meanwhile, talc litigation remains a wildcard, with bellwether trials and Daubert rulings in mid-2026 posing asymmetric downside. The orthopedics spin-off, while strategically sensible, adds complexity and dilutes near-term earnings visibility. Given the rich valuation and multiple risk factors, the prudent stance is to wait for a pullback toward $190 or for more concrete evidence of execution before adding exposure. The DeepValue report's base case of $215 suggests fair value near current levels, leaving little upside barring perfect execution.

Thesis delta

The news reinforces the importance of Tremfya and Icotyde in the post-Stelara strategy, but does not fundamentally alter the DeepValue thesis. The key shift is increased emphasis on Icotyde as a new growth vector, which may help bridge the gap to Darzalex LOE. However, the report's 'WAIT' rating remains appropriate given the lack of margin of safety and unresolved legal overhangs.